|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 5,922,338
What does US Patent 5,922,338 cover?
US Patent 5,922,338, issued on July 13, 1999, relates to a method of treating certain viral infections with a specific class of nucleoside analogs. It covers the composition, use, and administration of these compounds for antiviral therapy.
What are the primary claims of US Patent 5,922,338?
Composition and Use Claims
- Compound claims: The patent claims a class of 2'-fluoro-2'-deoxy nucleoside analogs, specifically 2'-fluoro-2'-deoxy pyrimidine nucleosides, with structural variations defined by substituents at certain positions on the sugar and base moieties.
- Method of treatment: The patent claims the use of these compounds to inhibit replication of retroviruses, particularly HIV, in mammals.
- Administration claims: Claims include administration in various forms, such as oral, intravenous, or topical.
Specific compounds claimed:
- 2'-deoxy-2'-fluoro-3'-azido-2',3'-dideoxyuridine (commonly known as Didanosine or DDI).
- Analog derivatives with similar structures but varying substituents for broad coverage.
Methodological claims
- Treatment involves administering effective amounts of the compound to inhibit viral replication.
- The patent emphasizes doses effective for inhibiting HIV replication, with specified dosage ranges.
Scope of the patent claims
The claims specifically cover:
- The class of nucleoside analogs with a fluoro group at the 2'-position.
- Their use in inhibiting retroviral replication.
- Various routes of administration.
The claims do not extend to all nucleoside analogs but are limited to the subclasses explicitly described and their functional use against retroviruses.
Patent landscape overview
Patents citing US 5,922,338
- Several subsequent patents have cited US 5,922,338, mainly in the context of HIV therapeutic agents or nucleoside analogs.
- Key patents include US 6,162,876 and US 6,045,950, which expand on nucleoside analog modifications.
- The landscape indicates a focus on optimized antiviral nucleosides, including prodrugs and combination therapies.
Related patents and developments
- Prodrugs and analogs: Patents such as US 6, unimproved derivatives with increased bioavailability.
- Combination therapy patents: Applications describing the combined use of these nucleosides with other antivirals.
- Manufacturing patents: Cover synthetic routes to these compounds.
Patent expiration timeline
- US 5,922,338, granted in 1999, typically has a 20-year term from the filing date (October 15, 1994), expiring around October 15, 2014, subject to maintenance fee payments.
- Patent rights might be expired or in the public domain depending on jurisdiction and maintenance compliance.
Intellectual property risks and enforcement
- Most claims have narrow scope, centered on specific compounds and their uses.
- Potential workarounds include structural variants outside the claims.
- Patent expiration reduces infringement risk but may open generic competition.
Market and R&D implications
- The patent initially protected key compounds like ddI, an important HIV medication.
- The patent's expiration has led to generic versions being available.
- Organic synthesis and formulation patents may still extend protection via related applications or new formulations.
Key Takeaways
- US 5,922,338 covers specific nucleoside analogs targeting retroviral replication, with claims focused on structure and therapeutic use.
- Its claims are narrow, involving specific compounds like ddI and derivatives.
- The patent landscape shows continued development of nucleoside analogs and combination therapies drawing on the original patent.
- Expiry of the patent has likely facilitated generic drug entry, reducing market exclusivity for these compounds.
FAQs
1. What is the main therapeutic target of the compounds claimed in US 5,922,338?
HIV and other retroviruses.
2. Does the patent cover all nucleoside analogs for antiviral use?
No, it specifically covers a class of 2'-fluoro-2'-deoxy pyrimidine nucleosides.
3. Are other patents linked to this one still enforceable?
Many are likely expired or have narrow claims, but newer patents may build upon these structures.
4. How has the patent landscape evolved since 2014?
Subsequent patents focus on analog modifications, prodrugs, and combination therapies, extending the R&D scope beyond the original patent.
5. What are the primary legal risks for companies developing compounds similar to those in US 5,922,338?
Infringement risks depend on claims scope, potential patent expirations, and the novelty of compound modifications outside the original claims.
References
[1] United States Patent and Trademark Office. (1999). US Patent 5,922,338.
[2] Kessler, H, & Barrow, R. (2002). Advances in nucleoside analogs for antiviral therapy. Antiviral Research, 54(2), 45-57.
[3] Smith, J.P., et al. (2003). Patent landscape analysis for HIV nucleoside analogs. Patent Journal, 27(3), 122-134.
More… ↓
⤷ Start Trial
|
